- Home
- PODC vs PRLD Comparison
PODC vs PRLD Comparison
Compare PODC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- PRLD
- Stock Information
- Founded
- PODC 2013
- PRLD 2016
- Country
- PODC United States
- PRLD United States
- Employees
- PODC N/A
- PRLD N/A
- Industry
- PODC
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- PODC
- PRLD Health Care
- Exchange
- PODC Nasdaq
- PRLD Nasdaq
- Market Cap
- PODC 39.6M
- PRLD 44.0M
- IPO Year
- PODC N/A
- PRLD 2020
- Fundamental
- Price
- PODC $1.70
- PRLD $1.19
- Analyst Decision
- PODC
- PRLD Strong Buy
- Analyst Count
- PODC 0
- PRLD 3
- Target Price
- PODC N/A
- PRLD $4.00
- AVG Volume (30 Days)
- PODC 70.8K
- PRLD 219.0K
- Earning Date
- PODC 11-06-2025
- PRLD 11-05-2025
- Dividend Yield
- PODC N/A
- PRLD N/A
- EPS Growth
- PODC N/A
- PRLD N/A
- EPS
- PODC N/A
- PRLD N/A
- Revenue
- PODC $53,954,000.00
- PRLD $7,000,000.00
- Revenue This Year
- PODC $17.91
- PRLD N/A
- Revenue Next Year
- PODC $14.41
- PRLD N/A
- P/E Ratio
- PODC N/A
- PRLD N/A
- Revenue Growth
- PODC 17.74
- PRLD N/A
- 52 Week Low
- PODC $1.10
- PRLD $0.61
- 52 Week High
- PODC $2.94
- PRLD $5.53
- Technical
- Relative Strength Index (RSI)
- PODC 51.61
- PRLD 58.29
- Support Level
- PODC $1.50
- PRLD $1.10
- Resistance Level
- PODC $1.60
- PRLD $1.26
- Average True Range (ATR)
- PODC 0.13
- PRLD 0.15
- MACD
- PODC 0.03
- PRLD -0.00
- Stochastic Oscillator
- PODC 73.96
- PRLD 74.84
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.